IMMEDIATE RELEASE 4-METHYL-3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]- N-[5-(4-METHYL- 1H-IMIDAZOL-1-YL)-3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE FORMULATION 4--3[[4-(3-)-2-]]-N-[5-(4--1H--1- )-3-()]

A solid dosage form of nilotinib is disclosed that comprises: (i) a core comprising 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide or a pharmaceutically acceptable salt thereof and excipients; and (ii) at least one polymer, sai...

Full description

Saved in:
Bibliographic Details
Main Authors LI, PING, COMFORT, ANN REESE, MAKAROV, ALEXEY, LI, SHOUFENG, BHARDWAJ, UPKAR, BORDAWEKAR, MANGESH SADASHIV
Format Patent
LanguageChinese
English
Published 02.01.2015
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:A solid dosage form of nilotinib is disclosed that comprises: (i) a core comprising 4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide or a pharmaceutically acceptable salt thereof and excipients; and (ii) at least one polymer, said polymer coating said core, wherein disintegration of said solid dosage form is delayed.
Bibliography:Application Number: HK20140110470